Search
Bladder/Urothelial
EAY191-E4 **11/30/23: EAY191-E4 is nearing the completion of its first stage of accrual, and no additional treatment assignments will be processed** **If biopsy needed, TBD at MBMC**
ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors
EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**
Molecular Analysis for Combination Therapy Choice
ALLIANCE A212102 **AT MBMC ONLY** **As of 8/1/23 the following Healthy Control Cohorts are Open (all others are Closed as of 2/22/23): Non-White Male Participants Age 60 or More Without Cancer Diagnosis and Non-White Male Participants Under Age 60 Without Cancer Diagnosis** **Effective with the release of Update #02, enrollment to the thyroid, melanoma, and sarcoma cancer cohorts has been closed.**
Blinded Reference Set For Multicancer Early Detection Blood Tests
URCC 19075 **MBMC ONLY**
Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)
URCC-21038
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting
A031803
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
URCC 18007
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
S1806
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
A031702 (Penile Cohort Suspended 3/13/20, Miscellaneous GU Tract Variants Cohort suspended 7/20/20, Small Cell Carcinoma/ Neuroendocrine of the Bladder Cohort suspended 4/21/21, Adenocarcinoma of the Bladder Cohort Closed 11/9/20, Renal Medullary Cohort suspended 6/23/21, Sarcomatoid Renal Cell Carcinoma suspended 8/12/21, Cohort C: Squamous Cell Carcinoma of the Bladder temporarily suspended 4/7/22 )
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
A031701
A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
